Telerobotic surgery is transitioning from experimental demonstrations to broader clinical and regulatory development, and SS Innovations International Inc. (NASDAQ: SSII) is positioning itself at the center of that shift. In a recent MedTech Dive article, the company's founder and CEO, cardiac surgeon Dr. Sudhir Srivastava, explained that robotic surgery is inherently a form of teleoperation. The critical technical challenge, he noted, is determining how much distance can be introduced between surgeon and patient without compromising responsiveness. This question is becoming more pressing as remote procedures gain traction worldwide.
SS Innovations has reported 195 robotic telesurgeries using its SSi Mantra system as of September 28, 2026, including cardiac procedures and long-distance operations. The company's installed base reached 244 SSi Mantra systems as of the same date, up 45% from the end of 2025, while cumulative procedures climbed to 14,503. The system has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka, and a new program established at HCG Hospital in Ahmedabad. These milestones underscore the growing adoption of the SSi Mantra platform in diverse clinical settings.
The company is currently pursuing U.S. FDA clearance and European Union CE marking to further expand into additional international markets. The recent MedTech Dive report, titled “Telerobotic surgery is advancing around the world. Will the US embrace it?,” examined the technology's development and the regulatory and infrastructure questions surrounding remote surgery. The article highlighted SS Innovations alongside larger medical-device companies and emerging robotics developers (https://ibn.fm/4ZLvL). For SS Innovations, the discussion comes as its SSi Mantra system accumulates valuable experience in telesurgery, which could inform future regulatory submissions and clinical adoption.
The implications of this progress are significant for the surgical robotics market. As telerobotic surgery gains ground, it promises to extend specialized surgical expertise to underserved regions, reduce travel burdens for patients, and enable real-time collaboration among surgeons across distances. However, regulatory frameworks in the U.S. and Europe must adapt to address the unique challenges of remote procedures, including latency, cybersecurity, and licensure across borders. SS Innovations' expanding real-world data could help shape those frameworks.
Investors and industry observers are closely monitoring SS Innovations' regulatory milestones. The company's newsroom, available at https://ibn.fm/SSII, provides ongoing updates. For a deeper dive into the company's telerobotic surgery position, see the full article at Read More>>. As remote procedures continue to gain momentum, SS Innovations' ability to secure FDA clearance and CE marking will be critical to its global expansion and competitive standing.
MissionIR, a specialized communications platform, distributes updates on SS Innovations and other companies. It operates within the Dynamic Brand Portfolio at IBN, which offers services including wire distribution through InvestorWire and editorial syndication to 5,000+ outlets. These channels help amplify news for companies like SS Innovations as they navigate the evolving telerobotic surgery landscape.
